CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$43.43 USD
+0.29 (0.67%)
Updated Mar 24, 2023 04:00 PM ET
After-Market: $43.45 +0.02 (0.05%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About Earnings Yield (TTM)
The company's trailing twelve month (TTM) Earning Yield is used to determine whether the company is undervalued or overvalued. The Earning yield an indicator of the company's earnings and the price paid for the stock. The calculation is the inverse of the P/E ratio. The most common use of the Earnings ratio is to compare it to other stocks and to compare the yields to the 10 Year T-Bill. If earnings go up, the yield goes up. If earnings go down, so does the yield. For example: If the yield on the S&P 500 is greater than the 10 Year T-Bill, stocks would be considered undervalued.
CRSP 43.43 +0.29(0.67%)
Will CRSP be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
CRISPR Therapeutics AG (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA
Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals
Other News for CRSP
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
IOVA, BBIO and IREN are among after hour movers
CRSP May 5th Options Begin Trading
FDA to back accelerated approval pathway for gene therapies
Crispr Therapeutics initiated with a Market Perform at Bernstein